Lyndra Therapeutics, Inc. announced that it will receive an equity round of funding on June 7, 2021. The transaction will include participation from Yipinhong Pharmaceutical (USA) Limited for $5,000,000. The transaction has been approved by the investors' parent Yipinhong Pharmaceutical Co.,Ltd. The company will sign Summary of C round Equity Financing Terms with the investor.

On June 8, 2021, the company announced that it will receive $64,999,999.5328 in funding. The company will issue 37,476,937 series C preferred shares at issue price of $1.7344 per share in the transaction. The shares are convertible, non-redeemable and non-cumulative. The shares carry non-cumulative fixed dividend rate of 6% per annum. The shares will be convertible in common shares at a fixed conversion price of $1.7344 per share. The round will be raised at post money valuation of $190,276,535. The company will issue securities pursuant to exemption provided under Regulation D.